Program
surabgene lomparvovec
Also written as “Surabgene Lomparvovec (ABBV-RGX-314)” and “Surabgene Lomparvovec”.
In AbbVie’s pipeline, VEGF
. Its studies are mostly in Macular Degeneration · Diabetic Retinopathy, led by AbbVie.
Furthest: phase 3, since May 28, 20252 company-led studies, 2 open or runningNext primary completion: Jun 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 22 open or running | phase 3since May 28, 2025 | May 28, 2025 | Jun 2028phase 3 · NCT07592273 |
- Named in AbbVie’s own pipeline as
Surabgene lomparvovec (ABBV-RGX-314)
, phase 3, as of Jul 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 28, 2025First study: phase 3 study in Neovascular Age-related Macular DegenerationFirst studyNCT07007065 · 561 planned · United States, Austria, Belgium and more
- Apr 24, 2026Phase 3 study in Diabetic RetinopathyNCT07592273 · 576 planned · United States, Puerto Rico
Ahead
- Jun 2028Primary completion: phase 3 study in Diabetic RetinopathyNCT07592273
- Mar 2033Primary completion: phase 3 study in Neovascular Age-related Macular DegenerationNCT07007065
TargetBeta
“VEGF”the company's pipeline, read by Claude · source
Other programs on VEGFA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Bevacizumabrule | Hoffmann-La Roche | phase 4 | 250 |
| Ranibizumabrule | Novartis | phase 4 | 108 |
| afliberceptrule | Regeneron Pharmaceuticals | phase 4 | 89 |
| faricimabrule | Hoffmann-La Roche | phase 4 | 17 |
| ivonescimabrule | Akeso | phase 3 | 48 |
| pumitamig | BioNTech | phase 3 | 34 |
| tivunatamig | Pfizer | phase 3 | 15 |
| suvemcitugrule | Simcere Pharmaceutical Group | phase 3 | 6 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14rule | Sinocelltech Group | phase 3 | 2 |
| ABBV-1480 | RemeGen | phase 3 | 2 |
| HLX37 | Fosun Pharma | phase 3 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001rule | Sichuan Kelun Pharmaceutical | phase 2 | 4 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07592273Diabetic Retinopathy · United States, Puerto Rico | 3 | Recruiting | Jun 2028 | 576 |
| NCT07007065Neovascular Age-related Macular Degeneration · United States, Austria, Belgium and more | 3 | Recruiting | Mar 2033 | 561 |
How it is read
Names in the registry
- “Surabgene Lomparvovec (ABBV-RGX-314)”, 1 entry
- “Surabgene Lomparvovec”, 1 entry
Conditions, from the studies’ own filings
- Macular Degeneration, 1 study
- Diabetic Retinopathy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.